Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472909 | 0.77 | NOS1 (0.35) | ACHE | |
| SCHEMBL4352728 | 0.76 | — | — | |
| SCHEMBL11480694 | 0.73 | ACHE (0.35) | ELANEPLAUACHE | |
| SCHEMBL16166152 | 0.71 | — | — | |
| SCHEMBL2765034 | 0.70 | PLAU (0.30) | ELANEPLAU | |
| SCHEMBL19114411 | 0.69 | ACHE (0.53) | ACHE | |
| SCHEMBL25291544 | 0.68 | ACHE (0.41) | ELANEACHE | |
| SCHEMBL11333618 | 0.68 | ACHE (0.38) | ELANEPLAUACHE | |
| SCHEMBL25293350 | 0.68 | ACHE (0.41) | ELANEPLAUACHE | |
| SCHEMBL15321819 | 0.68 | MAP4K1 (0.35) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ELANE 3521/4885PLAU 3645/4885ACHE 82/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | ELANE 3521/4885PLAU 3645/4885ACHE 82/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ELANE 3521/4885PLAU 3645/4885ACHE 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.